Patent details

Basic Information

Publication number:

92702

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP048148027

Legal Status:

Active

Application number:

92702

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/14/962 Moventig-naloxegol

Marketing Authorization Type:

Marketing Authorization Date:

10/12/2014

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Dates

Filing date:

29/04/2015

First Marketing Authorization date:

10/12/2014

Grant date:

29/07/2016

Activation date:

16/12/2024

Publication date:

29/07/2016

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

10/12/2029

SPC Extension Expiration:

10/12/2029

Rejection date:

Withdrawal date:

Owner

From:

29/04/2015

 

 

Name:

Nektar Therapeutics

Address:

455 Mission Bay Boulevard South Suite 100, San Francisco CA 94158, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

29/04/2015

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

BENTLEY Michael, D.

Address:

United States (US)

2

Name:

ZHAO Xuan

Address:

United States (US)

3

Name:

VIEGAS Tacey, X.

Address:

United States (US)

4

Name:

GOODIN Richard, R.

Address:

United States (US)

5

Name:

CHENG Lin

Address:

United States (US)

Publication

Bulletin

Bulletin Heading:

SPC3

Bulletin edition number:

2025/04

Publication date:

04/03/2025

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:

31/12/2025

Annual Fee Number:

22

Annual Fee Amount:

420 Euro

Expected Payer:

Last Annual Fee Payment Date:

13/12/2024

Last Annual Fee Paid Number:

21

Last Annual Fee Paid Amount:

410 Euro

Payer:

CPA GLOBAL THE IP PLATFORM

Filing date	Document type	Number of pages